A new federal policy halting government support for what it defines as dangerous gain-of-function research is scheduled to take effect in mid-November, and the scientific community is not in agreement about whether it will make Americans safer or slow the response to the next outbreak.
The United States Government Policy for Stopping High-Risk Life Sciences Research was released in July 2026. The Department of Health and Human Services and the Department of State issued a joint statement supporting it. The following day, the American Society for Microbiology said the policy's definitions are broad enough to shut down work the country needs.
For most readers, the honest answer is that this will not change anything you do this year. The question worth asking is narrower and more concrete: does this make a laboratory-origin outbreak less likely, and does it slow down the development of vaccines and treatments?
What the Policy Actually Covers
The policy targets two categories of work.
The first is dangerous gain-of-function research, abbreviated DGOF. Gain-of-function research broadly refers to studies in which infectious agents or toxins are altered to increase their ability to cause disease, spread, or infect new hosts. Researchers do this to anticipate viral evolution, design vaccines, and develop countermeasures. The policy's position is that a subset of this work carries risks that outweigh any benefit and should not be conducted domestically or abroad under any circumstance.
The second is international research of concern, or IROC, covering work conducted in collaboration with non-US researchers in foreign countries or entities of concern. For international proposals that do not fall into that category, agency officials will consult with the Secretary of State and apply a risk-based method to confirm that the performing institution meets or exceeds US biosafety and biosecurity standards.
Federal funding agencies will establish a government board to review proposed DGOF research submitted for funding and make recommendations to the funding agency. Principal investigators carry new obligations, including continuously evaluating their own work for DGOF and IROC and disclosing the names and affiliations of key personnel, including non-US collaborators and any work performed abroad.
The policy currently reaches only federally supported research. It also states that an interagency working group will explore additional regulatory, legislative, or other actions to manage risks from research with DGOF potential, including privately funded work.
The Administration's Case
HHS framed the policy as fulfilling a commitment to ensure federally supported life sciences research serves the public, and said an America First approach means taxpayer dollars never support dangerous gain-of-function research or proliferate other biological risks, whether the work happens in the United States or abroad.
On the question readers care about most, the departments were explicit. HHS said the United States will continue supporting biomedical research that develops "vaccines, therapeutics, diagnostics, and other lifesaving medical countermeasures" while subjecting the highest-risk work to rigorous safeguards.
The policy document itself states that it does not ban development of essential medical products and countermeasures to protect against bioterrorism and biological weapons, and does not prohibit international collaboration. It also emphasizes continued sharing of knowledge, products and results while working to improve laboratory biosafety and biosecurity worldwide.
Why Microbiologists Are Pushing Back
The American Society for Microbiology said it supports robust oversight of pathogen research, then argued that the policy, as written, goes further than oversight.
The society's central objection is definitional. It said the policy broadly defines several categories of research that, if shut down, would impede the nation's ability to address infectious disease threats and respond to future outbreaks. It described the distinction between dangerous gain-of-function research and potentially dangerous gain-of-function research as ambiguous as written, and warned that confusion in the research community will hinder work at the forefront of protecting Americans.
ASM also noted that the policy suggests some research previously performed in compliance with existing state, federal, international, and institutional oversight is now considered dangerous. It said the definitions are broad, the penalty for violation is high, and the resulting restrictions will inhibit national preparedness.
Allen Segal, chief strategy officer at ASM, told CIDRAP that the policy is a step toward getting the rest of the world to meet US standards, but argued the domestic approach should be different. He said the country should be investing in facilities and training "rather than taking the risk of prohibiting research to detect, prevent, and treat illness."
What Is Genuinely Unresolved
Both sides are making predictions, and neither can be evaluated yet.
The administration's position is that countermeasure development is carved out and preserved. ASM's position is that the carve-out will not hold in practice because the definitions sweep too broadly and researchers facing high penalties will avoid borderline work rather than risk it. Whether that chilling effect materializes is an empirical question that will only be answerable after implementation.
It is also unresolved how the review board will function, how quickly it will process proposals, and where exactly the line between dangerous and potentially dangerous work will be drawn in individual cases. The extension to privately funded research is under exploration, not decided.
What this does not change for households is straightforward. Vaccines, treatments and diagnostics currently available remain available. Nobody should alter a vaccination decision or a treatment plan based on a research funding policy. If the policy meaningfully slows countermeasure development, the effect would appear years from now in the speed of response to a future outbreak, not in anything on a pharmacy shelf today.
Implementation is slated for mid-November 2026. MedicalDaily will monitor for implementation guidance, the composition and procedures of the review board, and any interagency action on privately funded research.
Frequently Asked Questions
What is gain-of-function research? Studies in which infectious agents or toxins are altered to increase their ability to cause disease, transmit, or infect new hosts. Researchers use it to anticipate viral evolution and develop vaccines and countermeasures.
What does the new policy prohibit? Federal support for research the policy defines as dangerous gain-of-function, plus tightened oversight of international research of concern conducted with foreign countries or entities of concern.
Does it stop vaccine and treatment development? The administration says no, and the policy states it does not ban development of essential medical products and countermeasures. ASM argues the definitions are broad enough that some countermeasure-relevant work would be caught.
Does it apply to privately funded research? Not currently. The policy covers federally supported research, and states that an interagency working group will explore further action that could reach privately funded work.
When does it take effect? Implementation is slated for mid-November 2026. Details of the review process may be clarified before then.
Does this affect my vaccines or medications? No. Currently available vaccines, treatments and diagnostics are unaffected. Do not change any health decision based on a research funding policy.
Who reviews research under the policy? Federal funding agencies will establish a government board to review proposed dangerous gain-of-function research and make recommendations to the funding agency. Principal investigators must also self-evaluate and disclose collaborators.
